ABSTRACT
BACKGROUND RTS,S is the first malaria vaccine recommended for implementation among young children at risk. However, vaccine efficacy is modest and short-lived. Antibodies play the major role in vaccine-induced immunity, but knowledge on the induction, decay, and determinants of antibody function is limited, especially among children. Antibodies that promote opsonic phagocytosis and other cellular functions appear to be important contributors to RTS,S immunity.
METHODS We studied a phase IIb trial of RTS,S/AS02 conducted young children in malaria endemic regions of Mozambique. We evaluated the induction of antibodies targeting the circumsporozoite protein (CSP, vaccine antigen) that interact with Fcγ-receptors (FcRγs) and promote phagocytosis (neutrophils, monocytes, THP-1 cells), antibody-dependent respiratory burst (ADRB) by neutrophils, and natural killer (NK) cell activity, as well as the temporal kinetics of responses over 5 years of follow-up (ClinicalTrials.gov registry number NCT00197041).
RESULTS RTS,S vaccination induced CSP-specific IgG with FcγRIIa and FcγRIII binding activity and promoted phagocytosis by neutrophils, THP-1 monocytes, and primary human monocytes, neutrophil ADRB activity, and NK cell activation. Responses were highly heterogenous among children, and the magnitude of neutrophil phagocytosis by antibodies was relatively modest, which may reflect modest vaccine efficacy. Induction of functional antibodies was lower among children with higher malaria exposure. Functional antibodies largely declined within a year post-vaccination, consistent with the decline in vaccine efficacy over that time, and decay rates varied for different antibody parameters. Biostatistical modelling suggested IgG1 and IgG3 contribute in promoting FcγR binding and phagocytosis, and IgG targeting the NANP-repeat and C-terminal regions CSP were similarly important for functional activities.
CONCLUSIONS Results provide new insights to understand the modest and time-limited efficacy of RTS,S in children, and the induction of antibody functional activities. Improving the induction and maintenance of antibodies that promote phagocytosis and cellular functions, and combating the negative effect of malaria exposure on vaccine responses are potential strategies for improving RTS,S efficacy and longevity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (Program Grant and Senior Research Fellowship to JG Beeson; Project Grants to JG Beeson, and PM Hogarth), NHMRC Australian Centre for Research Excellence in Malaria Elimination (seed grant to G Feng), Australian Government Research Training Program Scholarship to LK. The Burnet Institute is supported by the NHMRC for Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support. JGB, GF, and LK are members of the NHMRC Australian Centre for Research Excellence in Malaria Elimination.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for this study was obtained from Alfred Health Human Research and Ethics Committee (protocol number 174/18); Mozambique National Health and Bioethics Committee; Hospital Clinic of Barcelona Ethics Committee; PATH Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used in the current study are available from the corresponding author on reasonable request and pending approval from ethics and regulatory committees where relevant. The Additional File (containing additional data analysis figures and tables) is available from the corresponding author on request. Specific materials and reagents used in immunologic assays can be provided dependent on availability.
LIST OF ABBREVIATIONS
- ADRB
- Antibody-dependent respiratory burst
- ADCC
- Antibody-dependent cellular cytotoxicity
- CSP
- circumsporozoite protein
- CT
- C-terminal domain
- FcγR
- Fcγ-receptor
- GLMM
- generalised linear mixed modelling
- M
- month
- PBS
- phosphate buffered saline
- RR
- rate ratio; ARR – adjusted rate ratio
- WHO
- World Health Organisation